These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 2380068)

  • 41. The influence of food on 8-methoxypsoralen serum concentration and minimal phototoxic dose.
    Bech-Thomsen N; Angelo HR; Knudsen EA
    Br J Dermatol; 1992 Dec; 127(6):620-4. PubMed ID: 1476921
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma levels of 8-methoxypsoralen after topical paint PUVA on nonpalmoplantar psoriatic skin.
    Hallman CP; Koo JY; Omohundro C; Lee J
    J Am Acad Dermatol; 1994 Aug; 31(2 Pt 1):273-5. PubMed ID: 8040415
    [No Abstract]   [Full Text] [Related]  

  • 43. Serum free 5-methoxypsoralen fraction in health and psoriasis: relationship with human serum albumin concentration.
    Muret P; Humbert P; Makki S; Bechtel P; Urien S; Tillement JP
    Arch Dermatol Res; 1993; 285(5):287-90. PubMed ID: 8379689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intraindividual variations of 8-methoxypsoralen plasma levels.
    Schäfer-Korting M; Korting HC
    Arch Dermatol Res; 1982; 272(1-2):1-7. PubMed ID: 7165313
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Standardizing 8-methoxypsoralen plasma profiles by using an emulsion form.
    Van Boven M; Roelandts R; Adriaens P; Daenens P; Degreef H; Kinget R
    J Am Acad Dermatol; 1985 May; 12(5 Pt 1):822-7. PubMed ID: 4008686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of 8-methoxypsoralen in serum and suction blister fluid.
    Lauharanta J; Juvakoski T; Kanerva L; Lassus A
    Arch Dermatol Res; 1982; 273(1-2):111-4. PubMed ID: 7184466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [8-Methoxypsoralen (8-MOP)-a new galenic form and its relation to 8-MOP serum levels (author's transl)].
    Nitsche V; Raff M; Bardach H
    Arch Dermatol Res; 1981; 271(1):11-7. PubMed ID: 7294879
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Food-induced increase in bioavailability of 5-methoxypsoralen.
    Ehrsson H; Wallin I; Ros AM; Eksborg S; Berg M
    Eur J Clin Pharmacol; 1994; 46(4):375-7. PubMed ID: 7957526
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A new micronized 5-methoxypsoralen preparation. Higher bioavailability and lower UVA dose requirement.
    Treffel P; Makki S; Humbert P; Khaldoun H; Agache P
    Acta Derm Venereol; 1992; 72(1):65-7. PubMed ID: 1350152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 8-Methoxypsoralen serum levels in poor responders to photochemotherapy. Importance of drug formulation and individual factors.
    Walther T; Haustein UF
    Int J Dermatol; 1991 Jul; 30(7):516-8. PubMed ID: 1769779
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-performance thin-layer chromatographic determination of 5-methoxypsoralen in serum from patients.
    Mignot B; Guillaume Y; Makki S; Murret E; Cavalli E; Truong TT; Thomassin M; Guinchard C
    J Chromatogr B Biomed Sci Appl; 1997 Oct; 700(1-2):283-5. PubMed ID: 9390742
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [5-Methoxypsoralen: bioavailability and pharmacokinetics].
    Nitsche V; Mascher H
    Arzneimittelforschung; 1982; 32(10):1338-41. PubMed ID: 6891237
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chronopharmacokinetics of 5-methoxypsoralen.
    Treffel P; Renaud A; Humbert P; Makki S; Faivre B; Agache PG
    Acta Derm Venereol; 1990; 70(6):515-7. PubMed ID: 1981428
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetic and clinical comparison of two 8-methoxypsoralen brands.
    Andersen KE; Menne T; Gammeltoft M; Hjorth N; Larsen E; Solgaard P
    Arch Dermatol Res; 1980; 268(1):23-9. PubMed ID: 7416795
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 8-Methoxypsoralen levels in blood of vitiligo patients and in skin, ophthalmic fluids, and ocular tissues of the guinea pig.
    Chakrabarti SG; Halder RM; Johnson BA; Minus HR; Pradhan TK; Kenney JA
    J Invest Dermatol; 1986 Aug; 87(2):276-9. PubMed ID: 3734475
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro dissolution rates of six 8-methoxypsoralen formulations.
    Stolk LM; Pasman A; Cormane RH; Van Zweiten PA
    Br J Dermatol; 1987 Jun; 116(6):813-21. PubMed ID: 3620342
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum levels of 8-methoxypsoralen in psoriasis patients using a new fluorodensitometric method.
    Herfst MJ; Koot-Gronsveld EA; de Wolff FA
    Arch Dermatol Res; 1978 Jun; 262(1):1-6. PubMed ID: 686816
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Problems with commercial formulations of 8-methoxypsoralen.
    Monbaliu JG; Bogaert MG; De Bersaques J; Hindryckx P
    Dermatologica; 1981; 163(6):468-73. PubMed ID: 7333402
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rapid and sensitive analysis of 8-methoxypsoralen in plasma.
    Gasparro FP; Battista J; Song J; Edelson RL
    J Invest Dermatol; 1988 Feb; 90(2):234-6. PubMed ID: 3339265
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.